Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.93 |
| ▸ | PGR | P06401 | 1/20 | 0.85 |
| ▸ | GLUL | P15104 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12956236 | 0.96 | NR3C1 (1.00) | NR3C1PGRGLUL | |
| SCHEMBL10116155 | 0.96 | NR3C1 (1.00) | NR3C1PGRGLUL | |
| SCHEMBL21024922 | 0.93 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL25913015 | 0.93 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1880230 | 0.93 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL12956251 | 0.93 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL13581493 | 0.92 | NR3C1 (0.85) | NR3C1PGRGLUL | |
| SCHEMBL12956166 | 0.92 | NR3C1 (1.00) | NR3C1PGRGLUL | |
| SCHEMBL11995501 | 0.92 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL13581501 | 0.91 | NR3C1 (1.00) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9821068-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9750816-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160289261-A1 | GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | NR3C1 2529/4885PGR 2952/4885GLUL 1135/4885 |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | NR3C1 2673/4885PGR 4642/4885GLUL 3826/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | NR3C1 4212/4885PGR 4362/4885GLUL 1696/4885 |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | NR3C1 2529/4885PGR 2952/4885GLUL 1135/4885 |
| US-20160289261-A1 | GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER | AR, NR3C1, NR3C2 | NR3C1 2/4885PGR 36/4885GLUL 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.